Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

BrightGene Plans $50 Million Shanghai STAR Board IPO

publication date: Sep 5, 2019

BrightGene Bio-Medical of Suzhou said the Shanghai Stock Exchange has accepted its filing for a STAR Board IPO. The company expects to raise $50 million in the offering. BrightGene focuses on innovative drugs along with difficult-to-make generic drug APIs and finished drugs. It is developing immunoncology treatments and orally available GLP-1RA peptides for type 2 diabetes. Earlier this year, BrightGene completed an $80 million pre-IPO funding led by Sequoia China. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China